Inhibitor proteazomu - bortezomib (Velcade) - v léčbě refrakterního mnohočetného myelomu První zkušenosti v České republice

Multiple myeloma is the second most prevalent and mostly fatal hematologic cancer. Further advances have been made in understanding the mechanisms involved in the myeloma pathogenesis and elucidation of critical signalling pathways as therapeutical targets. Proteasome inhibitors are the example of this new approach and bortezomib is the first agent in this class to enter clinical trials.